[go: up one dir, main page]

IS8293A - Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX - Google Patents

Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX

Info

Publication number
IS8293A
IS8293A IS8293A IS8293A IS8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A IS 8293 A IS8293 A IS 8293A
Authority
IS
Iceland
Prior art keywords
pyrrole
dione derivatives
liver receptor
regulate liver
regulate
Prior art date
Application number
IS8293A
Other languages
English (en)
Inventor
Boström Jonas
Brickmann Kay
Holm Patrik
Sandberg Pernilla
Swanson Marianne
Westerlund Christer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS8293A publication Critical patent/IS8293A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IS8293A 2003-07-11 2006-02-09 Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX IS8293A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
IS8293A true IS8293A (is) 2006-02-09

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8293A IS8293A (is) 2003-07-11 2006-02-09 Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX

Country Status (25)

Country Link
US (1) US7432288B2 (is)
EP (1) EP1646626B1 (is)
JP (1) JP2007521312A (is)
KR (1) KR20060035748A (is)
CN (1) CN1823061A (is)
AR (1) AR045721A1 (is)
AT (1) ATE399777T1 (is)
AU (1) AU2004255999B2 (is)
BR (1) BRPI0412472A (is)
CA (1) CA2532056A1 (is)
DE (1) DE602004014773D1 (is)
ES (1) ES2308204T3 (is)
GB (1) GB0316232D0 (is)
IL (1) IL172760A0 (is)
IS (1) IS8293A (is)
MX (1) MXPA06000414A (is)
MY (1) MY135821A (is)
NO (1) NO20060081L (is)
RU (1) RU2006102130A (is)
SA (1) SA04250204B1 (is)
TW (1) TW200503691A (is)
UA (1) UA82109C2 (is)
UY (1) UY28408A1 (is)
WO (1) WO2005005417A1 (is)
ZA (1) ZA200600222B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
KR20070094963A (ko) 2005-01-10 2007-09-27 아스트라제네카 아베 간 x 수용체 조절제로서 이소티아졸-3(2h)-온1,1-디옥사이드 유도체
JP2009535315A (ja) * 2006-04-28 2009-10-01 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 二環式テトラヒドロピロール化合物
CA2660963A1 (en) 2006-08-21 2008-02-28 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック, インコーポレイテッド Mekキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
WO2010003025A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
BR112013005425A2 (pt) 2010-09-07 2018-05-02 Snu R&Db Foundation compostos sesterterpenos e suas utilizações
BR112013013649A2 (pt) 2010-12-03 2016-09-06 Allergan Inc derivados de oxima azetidina como moduladores de receptor de esfingosina 1-fosfato (s1p)
CN103370102A (zh) 2010-12-03 2013-10-23 阿勒根公司 作为鞘氨醇1-磷酸(s1p)受体调节的新型肟衍生物
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
AU2017207291B2 (en) 2016-01-11 2023-06-15 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141080A0 (en) 1998-07-30 2002-02-10 Japan Tobacco Inc Disubstituted maleimide derivatives and pharmaceutical compositions containing the same
ATE284387T1 (de) 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク インコーポレイテッド Hdlコレステロール値を上昇させる組成物および方法
WO2001013916A1 (en) 1999-08-20 2001-03-01 Sagami Chemical Research Center Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
KR20060035748A (ko) 2006-04-26
CA2532056A1 (en) 2005-01-20
AU2004255999B2 (en) 2007-08-02
GB0316232D0 (en) 2003-08-13
AU2004255999A1 (en) 2005-01-20
RU2006102130A (ru) 2007-08-20
EP1646626B1 (en) 2008-07-02
UA82109C2 (uk) 2008-03-11
WO2005005417A1 (en) 2005-01-20
CN1823061A (zh) 2006-08-23
SA04250204B1 (ar) 2008-03-23
MXPA06000414A (es) 2006-03-17
DE602004014773D1 (de) 2008-08-14
ZA200600222B (en) 2007-04-25
HK1088320A1 (en) 2006-11-03
US20060235015A1 (en) 2006-10-19
IL172760A0 (en) 2006-04-10
UY28408A1 (es) 2005-02-28
EP1646626A1 (en) 2006-04-19
JP2007521312A (ja) 2007-08-02
MY135821A (en) 2008-07-31
ES2308204T3 (es) 2008-12-01
NO20060081L (no) 2006-02-08
US7432288B2 (en) 2008-10-07
ATE399777T1 (de) 2008-07-15
TW200503691A (en) 2005-02-01
AR045721A1 (es) 2005-11-09
BRPI0412472A (pt) 2006-09-19

Similar Documents

Publication Publication Date Title
IS8293A (is) Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX
ZA200606974B (en) Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
IS8466A (is) 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka
ZA200700351B (en) Compounds, compositions and methods
ZA200702479B (en) 4-heteroarylmethyl substituted phthalazinone derivatives
IL181408A0 (en) 4-heteroarylmethyl substituted phthalazinone derivatives
IS7884A (is) Díasepínóindól afleiður sem kínasa hindrar
ATE440085T1 (de) 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
DK1824856T3 (da) 2,4 (4,6)-pyrimidinderivater
IS7697A (is) Pýrimídýlsúlfónamíðafleiður sem miðlar flakkboðaviðtaka
IL183594A0 (en) Phenyl-piperazin methanone derivatives
IL183140A0 (en) Substituted benzoquinolizine derivatives
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
DE502005007723D1 (de) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone,
NL1030382A1 (nl) Gesubstitueerde N-sulfonylaminobenzyl-2-fenoxyaceetamide verbindingen.
ZA200700159B (en) Phenyl substituted [1.2]-oxazine-3,5-dione and dihydropyrone derivatives
AU156894S (en) Router
WO2006069159A3 (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
EP1811842A4 (en) IMMUNE ACTIVATION COMPOSITIONS BASED ON 3,3'-DIINDOLYLMETHANE
BRPI0509256A (pt) derivados de pirrolidina-3,4-dicarboxamida
DE502005000496D1 (de) Verstellvorrichtung
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
ES1058958Y (es) Mastil perfeccionado.
ES1058483Y (es) Bloque de asientos perfeccionado.
ES1057238Y (es) Buzon perfeccionado.